编者按：新岁启幕，津门聚贤，共话全球血液学发展新篇。2026年1月9日至11日，第六届中国血液学科发展大会在津召开，本届大会首设“国际论坛”，成为中外血液学领域深度对话的全新纽带。作为国际论坛主席之一，中国医学科学院血液病医院（中国医学科学院血液学研究所）Toshio Suda教授深耕血液学领域多年，兼具国际视野与学术影响力。《肿瘤瞭望-血液时讯》特邀Toshio Suda教授，分享国际论坛的创办初衷与核心意义，回顾学术亮点与合作成果，并为中国血液学更好融入国际舞台、深化全球合作提供建设性建议，推动中外学术交流迈向新阶段。
《肿瘤瞭望-血液时讯》：本届CASH大会首次设立国际论坛，旨在搭建中外血液学交流的新平台。作为论坛主席，您能分享设立国际论坛的初衷和意义吗？同时，您认为本次论坛有哪些重磅亮点值得国内外参会者特别关注？
Toshio Suda教授：国际论坛是本次CASH大会的一项重要创新，汇聚了包括中国在内的八个国家的专家学者参与，会议历时约四小时，围绕多项学科前沿议题开展了系统而深入的高水平学术交流。鉴于议程紧凑，与会专家普遍期待在未来持续开展此类高水平的学术交流与讨论。
论坛期间，在学术报告开始前，所院分别与孟加拉国和埃及的相关学术机构签署了合作谅解备忘录（MOU），标志着国际学术合作迈出重要一步。科学无国界！通过越来越多的国际合作，我们不仅能共享全球前沿学术资源，还能汲取不同文化带来的思维启发，这正是创立国际论坛的初衷。
Oncology Frontier-Hematology Frontier：The CASH 2026 Conference is establishing its first International Forum, aiming to create a new platform for academic exchange between Chinese and international hematology communities. As the Forum Chair, could you share the motivation and significance behind setting up this International Forum? Additionally, what major highlights of the Forum do you think participants, both domestic and international, should pay particular attention to?
Professor Toshio Suda: The International Forum represents a significant innovative initiative of the current CASH Congress. It successfully brought together experts and scholars from eight countries, including China. Spanning approximately four hours, the forum facilitated systematic, in-depth, and high-level academic exchanges focused on multiple cutting-edge topics across relevant disciplines. Given the compact schedule, participating experts expressed a strong and widespread expectation for the continued organization of such high-quality international academic dialogues and discussions in the future.
During the forum, prior to the commencement of the academic presentations, the institute signed Memoranda of Understanding (MOUs) with relevant academic institutions from Bangladesh and Egypt, respectively. This important milestone marks a meaningful advancement in the expansion of international academic collaboration.
Science knows no borders! Through increasing international cooperation, we not only gain access to and share cutting-edge global academic resources, but also benefit from the intellectual inspiration and diverse perspectives arising from different cultural backgrounds. This cross-cultural enrichment and mutual stimulation is precisely the original purpose and core motivation behind the establishment of the International Forum.
《肿瘤瞭望-血液时讯》：您于2024年4月加盟中国医学科学院血液病医院（中国医学科学院血液学研究所），这一决定背后有哪些考量？未来您对进一步加强中国血液学与国际接轨有哪些建议？
Toshio Suda教授：我认为，中国血液学研究在部分领域已达到世界领先水平，与欧美国家并驾齐驱。未来，中国研究人员应进一步提升国际化水平，不仅注重学术论文的发表，更应重视与国际同行的深入学术交流与合作。
Oncology Frontier-Hematology Frontier：You joined the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences in April 2024. What considerations influenced this decision, and what are your suggestions for further advancing the integration of Chinese hematology with the international community in the future?
Professor Toshio Suda: I believe that in certain fields, Chinese hematology research has reached a world-leading level and now stands shoulder to shoulder with Europe and the United States. Looking ahead, Chinese researchers should further enhance their internationalization, not only focusing on publishing academic papers but also emphasizing in-depth academic communication and collaboration with international peers.
专家简介
Toshio Suda 教授
中国医学科学院血液病医院（中国医学科学院血液学研究所）
Toshio Suda 多年来专注于造血干细胞（HSCs）及癌症相关造血干细胞微环境的研究。他的早期工作包括 HSC 的纯化、造血过程中细胞因子信号的鉴定，以及骨髓（BM）中 HSC 微环境的特征分析。尽管干细胞的分化遵循细胞自主的内在程序，但这一过程会受到干细胞微环境的影响。他发现了 HSC 的骨膜（endosteal）微环境（Cell, 2004），并在此基础上开创了氧化应激与干细胞衰老的新研究领域（Nature, 2004；Nature Med, 2006）。Suda 博士的研究表明，微环境细胞通过直接黏附以及分泌细胞因子、趋化因子和细胞外基质分子等体液微环境因子来调控干细胞，这些因子共同作用，形成一个功能性整体，以维持组织稳态。他的研究目标是将团队的研究成果转化应用于临床，开发干细胞微环境相关的癌症治疗策略，同时推动干细胞移植及血液系统疾病的治疗。Suda博士曾获得Metcalf奖（ISEH）、Mentor奖（ISEH）、E. Donnall Thomas讲座及奖项（ASH）以及新加坡MRC高级转化研究奖（STaR）。他目前担任《Experimental Hematology》主编。